Reported Sunday, Viking Therapeutics Reports 74% Of Subcutaneous VK2735 Participants Improved BMI Category Versus 15% On Placebo After 13 Weeks, With Improved Cardiometabolic Markers
Benzinga Newsdesk 2 days ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 WeeksVK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers
VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks
VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers
